Kornimate/medical-research-clean huggingface dataset:
clinical and radiological evaluation of acl reconstruction results

Conditions: Anterior Cruciate Ligament Injuries

Summary: the study is intended to include all patients who will undergo surgical reconstruction of the anterior cruciate ligament (acl). the patients will be monitored and evaluated preoperatively and also at 6 months and 1 years after the intervention through a clinical visit. such assessments will include the patient reported outcomes, the objective examination of the knee during a medical examination to quantify its stability and the radiological examination.

the literature presents a number of studies on the reconstruction of the anterior cruciate ligament, as well as numerous registers, but the identification of factors and parameters determining the outcomes remains largely debated. the study aims to analyze the potentially individual and operative parameters and identify the factors responsible for the clinical and radiological outcomes. in addition to collecting patient data in terms of features and clinical-radiological status, objective data will be documented and correlated. the study is intended to include all patients who will undergo surgical reconstruction of the anterior cruciate ligament (acl). these patients will be followed and evaluated preoperatively, at 6 months and at 1 years after surgery during a clinical visit. such assessments will include the patient reported outcomes, the objective examination of the knee during a medical examination to quantify its stability and the radiological examination.

Eligibility criteria:
inclusion criteria: * patients who have provided informed written written consent; * patients aged between 18 and 45;; * patients undergoing reconstructive surgical treatment of the anterior cruciate ligament (acl) exclusion criteria: * patients who have not signed informed consent; * patients undergoing any additional concomitant ligament repair or reconstruction at the same surgery * revision procedures * patients unable to lay still in an mri or ct scanner * patients with a torn acl or previous acl reconstruction in the contralateral knee.
effectiveness of telerehabilitation as an alternative to outpatient physiotherapy in the 1 month after arthroscopic rotator cuff repair surgery

Conditions: Rotator Cuff Injuries

Summary: the present study aims to verify whether telerehabilitation as an alternative to in-person treatment (both conducted by a physiotherapist) can be a valid option in terms of pain, recovery of the rom, shoulder functionality compared to those provided by therapy alone. face-to-face rehabilitation in patients undergoing arthroscopic rotator cuff repair surgery.


Eligibility criteria:
inclusion criteria: * male or female patients aged between 40 and 70 years * patients undergoing arthroscopic repair surgery of the rotator cuff tendons * start of outpatient treatment within 7 days of discharge from the orthopedic department of the argenta and delta hospitals * continuation of rehabilitation care at the ior physical and rehabilitation medicine service in argenta or at the physical therapy rehabilitation medicine service of the delta hospital. * patients who have provided informed consent exclusion criteria: * previous shoulder surgeries * difficulty understanding the italian language/language barrier * unavailability of it devices or stable wi-fi connection by the patient

Keywords: telerehabilitation physiotherapist rotator cuff repair surgery
pirfenidone as a radiosensitizer in the treatment of head and neck squamous cell carcinoma

Conditions: Head and Neck Squamous Cell Carcinoma; Radiotherapy; Radiosensitizer; Pirfenidone

Summary: head and neck squamous cell carcinoma (hnscc) is the sixth most common cancer worldwide, with a 5-year survival rate of less than 50%. radiotherapy is an important measure to control tumor recurrence. although radiotherapy has been widely used in patients with head and neck squamous cell carcinoma, the 2-year local recurrence rate of patients with locally advanced disease is still as high as 50%-60%, and the distant metastasis rate is as high as 20%-30%. this is associated with a lower radiosensitivity in hnscc. our previous study has confirmed that type i collagen secreted by cancer-associated fibroblasts (cafs) can enhance the radioresistance of head and neck squamous cell carcinoma. we also confirmed that pirfenidone could reduce type i collagen expression in cafs and enhance radiosensitivity in vitro and in vivo. therefore, we plan to translate the basic research into clinical practice and conduct a prospective interventional phase ii clinical trial to investigate the safety and efficacy of pirfenidone as a radiosensitizer in hnscc.


Eligibility criteria:
inclusion criteria: 1. be at least 18 years old; 2. provide written informed consent; 3. head and neck squamous cell carcinoma confirmed by biopsy (2022 who criteria); 4. no previous head and neck radiotherapy; 5. the presence of measurable lesions: no surgical treatment or postoperative imaging evaluation indicated that the tumor was not completely resected; 6. ecog ps: 0/1; 7. laboratory confirmation of good organ function. it should be given within 10 days before the first dose of treatment; 8) expected survival time ≥3 months. exclusion criteria: 1. no indications for or contraindications to radiotherapy after evaluation; 2. no oral medication; 3. pregnancy or lactation; 4. patients with known allergy to pirfenidone or other contraindications; 5. concurrent tumors (except cured basal cell or squamous cell skin cancer, and cervical cancer in situ); 6. patients had any serious coexisting medical conditions that could pose an unacceptable risk or negatively affect trial adherence. "for example, unstable heart disease requiring treatment, chronic hepatitis, kidney disease, poor condition, uncontrolled diabetes (fasting blood glucose \> 1.5 × uln), and mental illness."
the role of fapi pet-ct in diagnosing endometriosis

Conditions: Endometriosis

Summary: patients with suspected endometriosis scheduled for surgery will be identified. they will be asked to participate in a study evaluating the feasibility of fapi pet-ct in diagnosing endometriosis. the results will be compared with surgical findings, pathology, and other imaging techniques if available (i.e., mri, us).

this study investigates fapi pet-ct imaging in endometriosis diagnosis using a standardized protocol. participants will undergo two imaging sessions after a single fapi injection: first session: initial scan at 10 minutes post-injection follow-up scan at 30 minutes second session: additional scans at 60 and 80 minutes post-injection the protocol is designed to minimize radiation exposure through: single fapi injection two ultra-low dose ct scans limited field of view to suspected areas. nuclear medicine physicians will review pet-ct images independently, blinded to other imaging findings (mri, us). results will be shared with surgeons to guide the removal of suspicious lesions during surgery. all removed tissue will undergo pathological examination for confirmation. the study incorporates safety monitoring: observation during and after fapi administration follow-up contact at 24-48 hours post-scan documentation of any adverse events immediate reporting of unexpected findings. this research could potentially provide evidence for a novel, non-invasive method to comprehensively map endometriotic lesions, improving pre-operative planning.

Eligibility criteria:
inclusion criteria: * female participants aged 18-45 years * clinical suspicion of endometriosis based on symptoms * scheduled for diagnostic/therapeutic laparoscopic surgery * ability to understand and provide written informed consent * completed and signed radiation exposure documentation form exclusion criteria: * pregnant women or women who are breastfeeding * history of pelvic radiation therapy * known active malignancy * exposure to ionizing radiation for medical purposes within 12 months prior to enrollment

Keywords: endometriosis pet ct fibroblast activation protein inhibitor
safety and efficacy of ultra-rush sublingual immunotherapy in children with asthma allergic to grass pollen

Conditions: Asthma

Summary: the aim of the study is to assess the safety and efficacy of sublingual immunotherapy applied preseasonal and seasonal in ultra-rush scheme in children with bronchial asthma allergic to grass pollen. the investigators will assess clinical symptoms, reliever drugs usage, lung function, chosen markers of allergic inflammation, bronchial hyperreactivity with methacholine, and presence and type of allergy after two years of sublingual immunotherapy (slit) in children with asthma.

specific immunotherapy is the only causal treatment method of atopic diseases including bronchial asthma in children. sublingual immunotherapy seems to be the most promising alternative to traditional specific subcutaneous injection immunotherapy. the aim of the study is to assess the safety and efficacy of sublingual immunotherapy applied preseasonal and seasonal in ultra-rush scheme in children with bronchial asthma allergic to grass pollen. we will assess clinical symptoms, reliever drugs usage, lung function, chosen markers of allergic inflammation, bronchial hyperreactivity with methacholine, and presence and type of allergy after two years of slit in children with asthma. after two years the study will be unblinded, all the children will be given grass pollen allergen extract for a year.

Eligibility criteria:
inclusion criteria: * patients allergic to grasses pollen * patients with bronchial asthma * patients with controlled asthma * patients who were qualified for immunotherapy and gave written informed consent for immunotherapy exclusion criteria: * patients allergic for other perennial and seasonal allergens * patients with other chronic diseases that either put the patient at risk when participating in the study or could influence the results of the study or the patient's ability to participate in the study as judged by the investigator

Keywords: asthma sublingual immunotherapy children
prospective, randomized, non-inferiority investigation to compare effects of mepitel® one and urgotul® dressings in acute wound management (only)"

Conditions: Pain

Summary: to compare the effects of pain of the two dressings, mepitel® one and urgotul® in acute wound management.


Eligibility criteria:
inclusion criteria: 1. acute wound: traumatic wound (dermabrasion, skin tears, other), benign burn requiring the use of dressings 2. acute wound size between 3 cm² and 240 cm2 (wound could be covered by 2 investigational products maximum) 3. wound whose duration is ≤ 3 days 4. both gender with an age ≥ 18 years 5. subject able to understand and voluntarily sign the informed consent 6. subject able to follow the protocol 7. subject insured to the french social security system exclusion criteria: 1. surgical wound 2. infected, moderately to strongly exudative and haemorrhagic wound 3. diagnosed underlying disease (e.g. diabetic neuropathy, stroke, ...) which, as judged by the investigator, could interfere with the pain assessment 4. known allergy/hypersensitivity to any of the components of the investigational products 5. participation in other clinical investigation within one month prior to start of investigation 6. pregnant or breast-feeding women 7. person protected by a legal regime (tutorship or guardianship)

Keywords: acute wound management measured visual analoge scale
urinary tract infections in cirrhosis

Conditions: Liver Cirrhosis; Urinary Tract Infections

Summary: evaluate the prevalence and types of urinary tract infections, the features of the gut and urinary tract microbiota in cirrhosis, to assess its importance in the development of complications and outcomes of cirrhosis.

asymptomatic bacteriuria in an individual without urinary tract symptoms is defined by a mid-stream sample of urine showing bacterial growth \> 105 cfu/ml in two consecutive samples in women and in one single sample in men. a complicated urinary tract infections occurs in an individual in whom factors related to the host (e.g. underlying diabetes or immunosuppression) or specific anatomical or functional abnormalities related to the urinary tract. laboratory urine culture is the recommended method to determine the presence or absence of clinically significant bacteriuria. catheter-associated urinary tract infections refers to urinary tract infections occurring in a person whose urinary tract is currently catheterised or has been catheterised within the past 48 hours. signs and systemic symptoms compatible with сatheter-associated urinary tract infections include new onset or worsening of fever, rigors, altered mental status, malaise, or lethargy with no other identified cause, flank pain, costovertebral angle tenderness, acute haematuria, pelvic discomfort and in those whose catheters have been removed dysuria, urgent or frequent urination and suprapubic pain or tenderness. microbiologically, сatheter-associated urinary tract infections is defined by microbial growth of \> 103 cfu/ml of one or more bacterial species in a single catheter urine specimen or in a mid-stream voided urine specimen from a patient whose urethral, suprapubic, or condom catheter has been removed within the previous 48 hours.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of cirrhosis exclusion criteria: * human immunodeficiency virus or acquired immune deficiency syndrome * autoimmune diseases * oncology * organ transplantation
study to evaluate efficacy and safety of switching from tdf to taf in adults with chronic hepatitis b who are virologically suppressed

Conditions: Chronic Hepatitis B

Summary: the primary objectives of this study are to evaluate the efficacy, safety, and tolerability of switching to tenofovir alafenamide (taf) versus continuing tenofovir disoproxil fumarate (tdf) in virologically suppressed adults with chronic hepatitis b virus (hbv) infection.


Eligibility criteria:
key inclusion criteria: * must have the ability to understand and sign a written informed consent form; consent must be obtained prior to initiation of study procedures * adult male and non-pregnant, non-lactating females * documented evidence of chronic hepatitis b virus (hbv) infection previously * maintained on tenofovir disoproxil fumarate (tdf) 300 mg once daily for at least 48 weeks, and as monotherapy for chronic hepatitis b for at least 24 weeks with viral suppression (hbv dna \< lower limit of quantitation) for a minimum of 12 weeks prior to screening * adequate renal function * normal electrocardiogram key exclusion criteria: * pregnant women or women who are breastfeeding * males and females of reproductive potential who are unwilling to use an "effective", protocol-specified method(s) of contraception during the study. * co-infection with hepatitis c virus (hcv), hepatitis d virus (hdv), or human immunodeficiency virus (hiv) * evidence of hepatocellular carcinoma * current evidence of, or recent (≤ 5 year) history of clinical hepatic decompensation * abnormal hematological and biochemical parameters, including: * hemoglobin \< 10 g/dl * absolute neutrophil count \< 750/mm\^3 * platelets ≤ 50,000/mm\^3 * aspartate aminotransferase (ast) or alanine aminotransferase (alt) \> 5 × upper limit of the normal (uln) * albumin \< 3.0 mg/ dl * international normalized ratio (inr) \> 1.5 × uln (unless stable on anticoagulant regimen) * total bilirubin \> 2.5 × uln * received solid organ or bone marrow transplant * malignancy within 5 years prior to screening, with the exception of specific cancers that are cured by surgical resection (eg, basal cell skin cancer). individuals under evaluation for possible malignancy are not eligible. * currently receiving therapy with immunomodulators (eg, corticosteroids), nephrotoxic agents, or agents capable of modifying renal excretion * individuals receiving ongoing therapy with drugs not to be used with taf or tdf or individuals with a known hypersensitivity to study drugs, metabolites, or formulation excipients * current alcohol or substance abuse judged by the investigator to potentially interfere with compliance * any other clinical condition or prior therapy that, in the opinion of the investigator, would make the individual unsuitable for the study or unable to comply with dosing requirements. * use of investigational agents within 3 months of screening, unless allowed by the sponsor note: other protocol defined inclusion/exclusion criteria may apply.
safety, efficacy of pylera bid dosing in eradication of h. pylori

Conditions: Helicobacter Pylori Infection

Summary: the purpose of this study is to evaluate the effect of pylera when given twice a day. pylera approved treatment schedule is 3 pills taken 4 times daily, in addition to omeprazole given twice daily. in this trial, subjects with confirmed helicobacter pylori infection will receive pylera treatment and omeprazole twice daily.

this study will include three phases: screening, treatment and follow-up. screening: this phase will last a maximum of 15 days and subjects eligibility will be evaluated after informed consent signature. urea breath test (ubt) will be performed in addition to routine baseline evaluations (physical, lab test, etc). treatment: subjects will be treated for 10 days. a "confirmation of eligibility" visit will take place on day 0 and an "end-of-treatment" visit will take place between days 9-14. follow-up: approximately one month post-treatment, eradication of h. pylori will be confirmed through ubt

Eligibility criteria:
inclusion criteria: * positive h. pylori status through ubt testing exclusion criteria: * documented allergy to any of the drugs contained in the treatment regimen * severe renal insufficiency, renal failure or azotemia * previous surgery of the upper gastrointestinal tract * hepatic failure * pre-existing peripheral neuropathies * use of any experimental drug within 30 days prior to randomization

Keywords: helicobacter pylori infection quadruple therapy safety efficacy tolerability bid dosing
post-surgical delirium in patients undergoing open heart surgery.

Conditions: Delirium; Open Heart Surgery

Summary: post-surgical delirium in patients undergoing open heart surgery. introduction delirium occurs after open heart surgery may reach about 1/3 of the patients.(1) aim the aim of this study is to determine the incidence of delirium after open heart surgery and the associated risk factors in alexandria university hospital. patients and methods the study will be done on patients undergoing open heart surgery in alexandria university hospitals from january 5th 2019 till january 4th 2020. the 6-item cognitive impairment test (6cit) and spmsq questionnaire will be used. spmsq will be done preoperative and daily for 3 days postoperative, at day 7. phone call for spmsq will be done 3, 6 9 and 12 months after surgery.

post-surgical delirium in patients undergoing open heart surgery. introduction delirium occurs after open heart surgery may reach about 1/3 of the patients.(1) aim the aim of this study is to determine the incidence of delirium after open heart surgery and the associated risk factors in alexandria university hospital. patients and methods the study will be done on patients undergoing open heart surgery in alexandria university hospitals from january 5th 2019 till january 4th 2020. the 6-item cognitive impairment test (6cit) and spmsq questionnaire will be used. spmsq will be done preoperative and daily for 3 days postoperative, at day 7. phone call for spmsq will be done 3, 6 9 and 12 months after surgery. results results will be collected in tables and graphs. appropriate statistical analysis will be done. discussion results of the study will be discussed compared to other studies. references 1-jannati y, bagheri-nesami m, sohrabi m, yazdani-cherati j, mazdarani s. factors associated with post-surgical delirium in patients undergoing open heart surgery. oman med j. 2014 sep;29(5):340-5.

Eligibility criteria:
inclusion criteria:adult patients undergoing open heart surgery. - exclusion criteria: children, patient refusal. -
blood glucose testing and you

Conditions: Diabetes

Summary: the purpose of this study is to determine the difference between self-reported, estimated blood glucose level versus blood glucose levels measured with a blood glucose meter.


Eligibility criteria:
inclusion criteria: 1. males and females, 18 years of age and above 2. type 2 diabetes 3. able to speak, read, and understand english 4. willing to complete all study procedures exclusion criteria: 1. type 1 diabetes 2. currently a user of continuous glucose monitoring system 3. currently pregnant 4. hemophilia or any other bleeding disorder 5. employee of competitive medical device company 6. cognitive disorder or other condition which, in the opinion of the investigator (or designee), would put the person at risk or seriously compromise the integrity of the study
effects of low-intensity excoporeal shock wave therapy (lieswt) on women with pelvic floor dysfunction

Conditions: Overactive Bladder; Stress Incontinence; Interstitial Cystitis; Female Sexual Dysfunction

Summary: 1. this study needles female reproductive urinary tract, likely bladder hyperactivity, active urinary incontinence and interstitial cystitis, observation use of low-capacity seismic wave (lieswt) therapy combined with combined platelet plasma (prp), improved bone basin pain and female urinary incontinence. 2. lieswt to arousal the clitoris angiogenesis to prevent female sexual dysfunction.

collect 120 women(a. overactive bladder、b. stress incontinence、c. interstitial cystitis d. female sexual dysfunction), low energy extracorporeal shock wave (lieswt) therapy once a week, duration 8 weeks(b.、c. prp treatment at 1, 5, 9 weeks), and to complete all treatment after 4 weeks and 24 weeks back to the clinic, evaluation questionnaire (oabss、udi-6、iiq-7、iciq-sf、popdi-6、fsfi)、urinary tract dynamics test、urination log、cotton pad test、blood test(esr、ca125、cbc、crp). ○dlow energy extracorporeal shock wave (lieswt) therapy once a week, duration 4 weeks, and to complete all treatment 4th and after 4 weeks back to the clinic, pelvic doppler ultrasound ,evaluation questionnaire (oabss、udi-6、iiq-7、iciq-sf、popdi-6、fsfi).

Eligibility criteria:
inclusion criteria: 1. one of the following symptoms can be included: 1. overactive bladder 2. stress incontinence 3. interstitial cystitis 4. not menopause and female sexual dysfunction (fsfi scores\< 26) 2. the blood test confirmed that the number of platelets was 150,000 to 450,000 / ul, and the coagulation function (pt) index was normal. 3. women over 20 years. exclusion criteria: 1. no uti during the past week. 2. patients with poorly controlled diabetes, spinal cord injury, brain disease and neurogenic disease. 3. urinary symptoms of inflammation(bladder stones、hematuria、urethral syndrome). 4. patients with acute or chronic infectious diseases. 5. patients with acute or chronic cardiovascular disease. 6. patients with a history of chronic liver and kidney disease. 7. patients receiving anticoagulant therapy(aspirin and nsaids cox-1). 8. patients with bleeding disorders. 9. receive low energy extracorporeal shock wave treatment within 1 month before entering the trial. 10. urinary incontinence need to install the catheter. 11. pregnant women. 12. unable to sign the consent form.

Keywords: lieswt